$ISCO
International Stem Cell CORP

2014 Q1 Form 10-Q Financial Statement

#000119312514195476 Filed on May 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q1
Revenue $1.649M $1.285M
YoY Change 28.33% 18.98%
Cost Of Revenue $439.0K $334.0K
YoY Change 31.44% 4.38%
Gross Profit $1.210M $951.0K
YoY Change 27.23% 26.8%
Gross Profit Margin 73.38% 74.01%
Selling, General & Admin $2.317M $1.943M
YoY Change 19.25% -23.5%
% of Gross Profit 191.49% 204.31%
Research & Development $958.0K $721.0K
YoY Change 32.87% -23.3%
% of Gross Profit 79.17% 75.81%
Depreciation & Amortization $116.0K $116.0K
YoY Change 0.0% -10.77%
% of Gross Profit 9.59% 12.2%
Operating Expenses $3.275M $2.664M
YoY Change 22.94% -23.45%
Operating Profit -$2.065M -$1.713M
YoY Change 20.55% -37.25%
Interest Expense $1.000K $1.000K
YoY Change 0.0% -97.5%
% of Operating Profit
Other Income/Expense, Net $630.0K $1.000K
YoY Change 62900.0%
Pretax Income -$1.435M -$1.712M
YoY Change -16.18% -36.12%
Income Tax
% Of Pretax Income
Net Earnings -$1.435M -$1.712M
YoY Change -16.18% -36.12%
Net Earnings / Revenue -87.02% -133.23%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.412M -$2.342M
COMMON SHARES
Basic Shares Outstanding 153.5M
Diluted Shares Outstanding 153.5M

Balance Sheet

Concept 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $990.0K $1.910M
YoY Change -48.17% -68.22%
Cash & Equivalents $991.0K $1.912M
Short-Term Investments
Other Short-Term Assets $690.0K $490.0K
YoY Change 40.82% 63.33%
Inventory $1.357M $1.210M
Prepaid Expenses
Receivables $501.0K $380.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.535M $3.990M
YoY Change -11.4% -48.85%
LONG-TERM ASSETS
Property, Plant & Equipment $742.0K $1.030M
YoY Change -27.96% -24.26%
Goodwill
YoY Change
Intangibles $2.342M
YoY Change
Long-Term Investments
YoY Change
Other Assets $30.00K $20.00K
YoY Change 50.0% 0.0%
Total Long-Term Assets $3.117M $2.830M
YoY Change 10.14% 1.43%
TOTAL ASSETS
Total Short-Term Assets $3.535M $3.990M
Total Long-Term Assets $3.117M $2.830M
Total Assets $6.652M $6.820M
YoY Change -2.46% -35.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $518.0K $430.0K
YoY Change 20.47% -40.28%
Accrued Expenses $952.0K $750.0K
YoY Change 26.93% -7.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.048M $1.590M
YoY Change 280.38% -18.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.048M $1.590M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $6.050M $1.590M
YoY Change 280.5% -18.88%
SHAREHOLDERS EQUITY
Retained Earnings -$83.71M
YoY Change
Common Stock $157.0K $2.025M
YoY Change -92.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.337M $5.220M
YoY Change
Total Liabilities & Shareholders Equity $6.652M $6.820M
YoY Change -2.46% -35.6%

Cashflow Statement

Concept 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$1.435M -$1.712M
YoY Change -16.18% -36.12%
Depreciation, Depletion And Amortization $116.0K $116.0K
YoY Change 0.0% -10.77%
Cash From Operating Activities -$2.030M -$1.850M
YoY Change 9.73% -8.87%
INVESTING ACTIVITIES
Capital Expenditures $13.00K -$170.0K
YoY Change -107.65% -22.73%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$160.0K -$170.0K
YoY Change -5.88% -22.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.104M $1.000M
YoY Change 10.4% -85.78%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 940.0K 3.270M
YoY Change -71.25% -52.75%
NET CHANGE
Cash From Operating Activities -2.030M -1.850M
Cash From Investing Activities -160.0K -170.0K
Cash From Financing Activities 940.0K 3.270M
Net Change In Cash -1.250M 1.250M
YoY Change -200.0% -73.23%
FREE CASH FLOW
Cash From Operating Activities -$2.030M -$1.850M
Capital Expenditures $13.00K -$170.0K
Free Cash Flow -$2.043M -$1.680M
YoY Change 21.61% -7.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
159104553 shares
CY2013Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2500000 shares
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.20
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
1000000
CY2006Q3 isco Common Stock In Subsidiary Company
CommonStockInSubsidiaryCompany
20000000 shares
CY2008Q2 isco Specified Amount Of Revenue To Be Utilized First For Advances
SpecifiedAmountOfRevenueToBeUtilizedFirstForAdvances
250000
CY2008Q2 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 isco Warrant Liabilities
WarrantLiabilities
4485000
CY2013Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
9462500 shares
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
6811745 shares
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1912000
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
156904553 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
45650654 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
156904553 shares
CY2014Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
128835341 shares
CY2014Q1 us-gaap Share Price
SharePrice
0.19
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
44983988 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
200000 shares
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.15
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3848655 shares
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
952000
CY2014Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1635000
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
79212000
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
518000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6048000
CY2014Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4302000
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-4337000
CY2014Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
19000
CY2014Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
26000
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83706000
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2014Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
525000
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
157000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6652000
CY2014Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
130000
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2018000
CY2014Q1 us-gaap Inventory Gross
InventoryGross
1487000
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
636000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Receivable In Three Years
OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
101000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Receivable In Four Years
OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
3000
CY2014Q1 us-gaap Assets Current
AssetsCurrent
3535000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Receivable In Two Years
OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
397000
CY2014Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2342000
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
64000
CY2014Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2014Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
397000
CY2014Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
5000
CY2014Q1 us-gaap Assets
Assets
6652000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
991000
CY2014Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
178000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
792000
CY2014Q1 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
2867000
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
501000
CY2014Q1 us-gaap Inventory Net
InventoryNet
1357000
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
63000
CY2014Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2377000
CY2014Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2321000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear
291000
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
64000
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
64000
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1500000
CY2014Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
912000
CY2014Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
48000
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
742000
CY2014Q1 isco Advances
Advances
250000
CY2014Q1 isco Deposits And Other Assets
DepositsAndOtherAssets
33000
CY2014Q1 isco Common Stock Capital Shares Reserved For Future Issuance Of Exercise Of Outstanding Warrants
CommonStockCapitalSharesReservedForFutureIssuanceOfExerciseOfOutstandingWarrants
37888154 shares
CY2014Q1 isco Revenue Realized From Agreement
RevenueRealizedFromAgreement
0
CY2014Q1 isco Warrant To Purchase Common Stock
WarrantToPurchaseCommonStock
4302000
CY2014Q1 isco Percentage Of Ownership In Issue And Outstanding Share Of Common Stock Parent Company
PercentageOfOwnershipInIssueAndOutstandingShareOfCommonStockParentCompany
0.937 pure
CY2014Q1 isco Share Based Compensation Arrangement By Share Based Payments Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
0.166
CY2014Q1 isco Warrant Liabilities
WarrantLiabilities
4302000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
3500000 shares
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-1758000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
654000
CY2012Q4 isco Share Based Compensation Arrangement By Share Based Payments Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
0.336
CY2012Q4 isco Percentage Of Rate Of Return On Product Guarantee
PercentageOfRateOfReturnOnProductGuarantee
0.03 pure
CY2013Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5062500 shares
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10125000 shares
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.20
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
2025000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
151175053 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
151175053 shares
CY2013Q4 us-gaap Share Price
SharePrice
0.21
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
44983988 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
200000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.15
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1290000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1534000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
77897000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
532000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7021000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4925000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-4223000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
19000
CY2013Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
21000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82271000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3000
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
510000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
151000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7739000
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
126000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets Current
AssetsCurrent
4626000
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2250000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
446000
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
5000
CY2013Q4 us-gaap Assets
Assets
7739000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2243000
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
147000
CY2013Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
2760000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
306000
CY2013Q4 us-gaap Inventory Net
InventoryNet
1369000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2364000
CY2013Q4 us-gaap Inventory Gross
InventoryGross
1495000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
658000
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
902000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
830000
CY2013Q4 isco Advances
Advances
250000
CY2013Q4 isco Deposits And Other Assets
DepositsAndOtherAssets
33000
CY2013Q4 isco Common Stock Capital Shares Reserved For Future Issuance Of Exercise Of Outstanding Warrants
CommonStockCapitalSharesReservedForFutureIssuanceOfExerciseOfOutstandingWarrants
37888154 shares
CY2013Q4 isco Warrant To Purchase Common Stock
WarrantToPurchaseCommonStock
4925000
CY2013Q4 isco Share Based Compensation Arrangement By Share Based Payments Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
0.166
CY2013Q4 isco Warrant Liabilities
WarrantLiabilities
4925000
CY2013Q4 isco Percentage Of Rate Of Return On Product Guarantee
PercentageOfRateOfReturnOnProductGuarantee
0.03 pure
CY2003Q4 us-gaap License Costs
LicenseCosts
340000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Reclassification</i></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Certain amounts within the unaudited condensed consolidated statements of operations for the prior period have been reclassified to conform to the current period presentation. These reclassifications had no impact on the Company&#x2019;s previously reported results of operations.</p> </div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values and transactions using the Black-Scholes option pricing model, e.g., warrants and stock options, as well as the Monte-Carlo valuation method for certain warrants. Actual results could differ from those estimates.</p> </div>
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Deferred Revenue and Allowance for Sales Returns</i></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company recognizes revenue from product sales when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed or determinable, and collectability is reasonably assured. However, the LSC products have a 30-day product return guarantee for website sales. The Company has estimated the historical rate of returns for the 30-day product return guarantee to be approximately 3% for the years ended December&#xA0;31, 2013 and 2012. At March&#xA0;31, 2014 and December&#xA0;31, 2013, the estimated allowance for sales returns was $10,000. At March&#xA0;31, 2014 and December&#xA0;31, 2013, net deferred revenue totaled $0 and $3,000, respectively.</p> </div>
CY2004Q2 isco Additional License Fees
AdditionalLicenseFees
400000
CY2008Q2 isco Number Of Accredited Investors
NumberOfAccreditedInvestors
5 Investor
CY2013Q1 isco Stock Issued During Period New Issues Value Per Share
StockIssuedDuringPeriodNewIssuesValuePerShare
0.20
CY2013Q1 isco Common Stock Warrants Issued To Purchase Common Stock Percentage
CommonStockWarrantsIssuedToPurchaseCommonStockPercentage
0.50 pure
CY2013Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2377000
CY2013Q3 isco Agents Fees Percentage On Gross Proceeds
AgentsFeesPercentageOnGrossProceeds
0.05 pure
CY2013Q3 isco Percentage Of Gross Proceeds Paid To Agent
PercentageOfGrossProceedsPaidToAgent
0.05 pure
CY2013Q3 isco Fair Value Of Warrant Liabilities In Excess Of Proceeds
FairValueOfWarrantLiabilitiesInExcessOfProceeds
1390000
CY2004Q1 isco Additional Option Fees
AdditionalOptionFees
22500
CY2013Q1 isco Stock Issued During Period New Issues Value Per Share
StockIssuedDuringPeriodNewIssuesValuePerShare
0.20
CY2013Q1 isco Common Stock Warrants Issued To Purchase Common Stock Percentage
CommonStockWarrantsIssuedToPurchaseCommonStockPercentage
0.50 pure
CY2011 isco Share Based Compensation Arrangement By Share Based Payment Award Vesting Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingTerm
Four quarters
CY2013 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2013-10-24
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
64983988 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.843 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
6545178 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
Monte-Carlo simulation model
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
16954822 shares
CY2013 us-gaap Revenues
Revenues
6147000
CY2013 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
240000
CY2013 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
2700000
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
5986000
CY2013 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
3381000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-10479000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1693000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
CY2013 us-gaap Sales Allowances Goods
SalesAllowancesGoods
10000
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
1815000
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-754000
CY2013 isco Right Of Return Guarantee Period
RightOfReturnGuaranteePeriod
P30D
CY2013 isco Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
0.147
CY2013 isco Common Stock Issuance Cost
CommonStockIssuanceCost
178000
CY2013 isco Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
0.156
CY2013 isco Commissions
Commissions
98000
CY2013 isco Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice
0.198
CY2013 isco Potential Common Stock Value To Be Sold
PotentialCommonStockValueToBeSold
10250000
CY2012 isco Right Of Return Guarantee Period
RightOfReturnGuaranteePeriod
P30D
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
15864448 shares
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
103566000 shares
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1847000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2013Q1 us-gaap Revenues
Revenues
1285000
CY2013Q1 us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
4000
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1285000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1712000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1713000
CY2013Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
168000
CY2013Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
36000
CY2013Q1 us-gaap Interest Paid
InterestPaid
1000
CY2013Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
16000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1712000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
41000
CY2013Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
68000
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
2998000
CY2013Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
74000
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2013Q1 isco Related Party Rent Expense
RelatedPartyRentExpense
28000
CY2013Q1 isco Change In Inventory Obsolescence
ChangeInInventoryObsolescence
4000
CY2014Q1 dei Trading Symbol
TradingSymbol
ISCO
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
International Stem Cell CORP
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
111000
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-1712000
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
11000
CY2013Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1432000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3273000
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-70000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1258000
CY2013Q1 us-gaap Marketing Expense
MarketingExpense
511000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-168000
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
16000
CY2013Q1 us-gaap Interest Expense
InterestExpense
1000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-539000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3289000
CY2013Q1 us-gaap Cost Of Revenue
CostOfRevenue
334000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
721000
CY2013Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
19000
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
116000
CY2013Q1 us-gaap Depreciation
Depreciation
101000
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
409000
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001355790
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
19431138 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.839 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
Monte-Carlo simulation model
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
153488000 shares
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2031000
CY2014Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2014Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 Segment
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
2016-09-30
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2014Q1 us-gaap Revenues
Revenues
1649000
CY2014Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
39000
CY2014Q1 us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
8000
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1649000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1435000
CY2014Q1 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
13000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2065000
CY2014Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
143000
CY2014Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-22000
CY2014Q1 us-gaap Interest Paid
InterestPaid
1000
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
169000
CY2014Q1 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
935000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1435000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
195000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
630000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-1435000
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-8000
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
347000
CY2014Q1 us-gaap Sales Allowances Goods
SalesAllowancesGoods
10000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
29000
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-623000
CY2014Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
39000
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
3714000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1648000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
935000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1252000
CY2014Q1 us-gaap Marketing Expense
MarketingExpense
669000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-156000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-338000
CY2014Q1 us-gaap Interest Expense
InterestExpense
1000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-14000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1104000
CY2014Q1 us-gaap Acquisition Costs
AcquisitionCosts
2078000
CY2014Q1 us-gaap Cost Of Revenue
CostOfRevenue
439000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
958000
CY2014Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
5000
CY2014Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
36000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
116000
CY2014Q1 us-gaap Depreciation
Depreciation
101000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
347000
CY2014Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
623000
CY2014Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
79000
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2014Q1 isco Warrant Term
WarrantTerm
P5Y
CY2014Q1 isco Burn Rate Excluding Capital Expenditures And Patent Costs
BurnRateExcludingCapitalExpendituresAndPatentCosts
677000
CY2014Q1 isco Number Of Products
NumberOfProducts
130 Product
CY2014Q1 isco Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
2 Subsidiary
CY2014Q1 isco Common Stock Issuance Cost
CommonStockIssuanceCost
169000
CY2014Q1 isco Related Party Rent Expense
RelatedPartyRentExpense
35000
CY2014Q1 isco Change In Inventory Obsolescence
ChangeInInventoryObsolescence
4000
CY2014Q1 isco Capital Expenditures And Patent Costs
CapitalExpendituresAndPatentCosts
52000

Files In Submission

Name View Source Status
0001193125-14-195476-index-headers.html Edgar Link pending
0001193125-14-195476-index.html Edgar Link pending
0001193125-14-195476.txt Edgar Link pending
0001193125-14-195476-xbrl.zip Edgar Link pending
d690307d10q.htm Edgar Link pending
d690307dex311.htm Edgar Link pending
d690307dex312.htm Edgar Link pending
d690307dex321.htm Edgar Link pending
d690307dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
isco-20140331.xml Edgar Link completed
isco-20140331.xsd Edgar Link pending
isco-20140331_cal.xml Edgar Link unprocessable
isco-20140331_def.xml Edgar Link unprocessable
isco-20140331_lab.xml Edgar Link unprocessable
isco-20140331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending